display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced mGC or mGEJC
mGC or mGEJC - L2 - all populationmGC or mGEJC - L2 - PDL1 positive
anti-PD-(L)1
avelumab based treatment
avelumab alone JAVELIN Gastric 300
nivolumab based treatment
nivolumab alone ATTRACTION-2 ...
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-061 ... KEYNOTE-061 ...

Study type: